Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | MPNs: looking to ASH 2019

Claire Harrison • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms CPI-0610 Luspatercept Navitoclax

Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares what myeloproliferative neoplasms (MPNs) updates she is looking forward to hearing about at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition. This interview took place at the MPN Advances Day 2019 in London, UK.

More from Claire Harrison

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
1:58
The value of novel JAK2 and CALR-targeted therapies in MPNs
Claire Harrison • 24 Apr 2023
1:39
The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison • 24 Apr 2023
2:33
Optimizing current treatment approaches in myelofibrosis
Claire Harrison • 24 Apr 2023

Related Videos

1:35
Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh • 25 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals